Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ABILIFY 2 MG TABLET

ARIPIPRAZOLE
$18.6473per EA
High Outlier

Strength

2 mg/1

Manufacturer

Otsuka America Pharmaceutical Inc.

NDC

59148000613

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

ARIPIPRAZOLE

Approval Type

New Drug (NDA)

FDA Application

NDA021436

On Market Since

11/15/2002

Pharmacological Classes

Atypical Antipsychotic

Price History

1W

0.0%

1M

-0.0%

3M

+0.1%

6M

+0.0%

1Y

+0.0%

3Y

-34.5%

5Y

-34.5%

All

-14.6%

Generic Alternatives

Save up to 99%

1 alternative • Same active ingredient

ARIPIPRAZOLE 2 MG TABLET
Generic
16729027801•Accord Healthcare Inc.
$0.1036
Save 99%

Related Drugs

Same classification

SEROQUEL 25 MG TABLET
Brand
00310027510•AstraZeneca Pharmaceuticals LP
$3.7050
per EA
RISPERDAL 0.5 MG TABLET
Brand
50458030201•Janssen Pharmaceuticals Inc.
$4.3928
per EA
RISPERDAL 0.5 MG TABLET
Brand
50458030206•Janssen Pharmaceuticals Inc.
$4.3928
per EA
RISPERDAL 1 MG TABLET
Brand
50458030001•Janssen Pharmaceuticals Inc.
$4.6958
per EA
RISPERDAL 1 MG TABLET
Brand
50458030006•Janssen Pharmaceuticals Inc.
$4.6958
per EA
RISPERDAL 1 MG/ML SOLUTION
Brand
50458030503•Janssen Pharmaceuticals Inc.
$5.2507
per ML
SEROQUEL 50 MG TABLET
Brand
00310027810•AstraZeneca Pharmaceuticals LP
$6.0917
per EA
CLOZARIL 25 MG TABLET
Brand
69809012605•HLS Therapeutics (USA), Inc.
$6.2959
per EA
SEROQUEL 100 MG TABLET
Brand
00310027110•AstraZeneca Pharmaceuticals LP
$6.3802
per EA
SEROQUEL XR 50 MG TABLET
Brand
00310028060•AstraZeneca Pharmaceuticals LP
$7.7675
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy